136 related articles for article (PubMed ID: 33971157)
41. Expression pattern of peptidylarginine deiminase in rat and human Schwann cells.
Keilhoff G; Prell T; Langnaese K; Mawrin C; Simon M; Fansa H; Nicholas AP
Dev Neurobiol; 2008 Jan; 68(1):101-14. PubMed ID: 17948239
[TBL] [Abstract][Full Text] [Related]
42. Potential protein targets of the peptidylarginine deiminase 2 and peptidylarginine deiminase 4 enzymes in rheumatoid synovial tissue and its possible meaning.
Badillo-Soto MA; Rodríguez-Rodríguez M; Pérez-Pérez ME; Daza-Benitez L; Bollain-Y-Goytia JJ; Carrillo-Jiménez MA; Avalos-Díaz E; Herrera-Esparza R
Eur J Rheumatol; 2016 Jun; 3(2):44-49. PubMed ID: 27708970
[TBL] [Abstract][Full Text] [Related]
43. Structure and mechanism of a bacterial host-protein citrullinating virulence factor, Porphyromonas gingivalis peptidylarginine deiminase.
Goulas T; Mizgalska D; Garcia-Ferrer I; Kantyka T; Guevara T; Szmigielski B; Sroka A; Millán C; Usón I; Veillard F; Potempa B; Mydel P; Solà M; Potempa J; Gomis-Rüth FX
Sci Rep; 2015 Jul; 5():11969. PubMed ID: 26132828
[TBL] [Abstract][Full Text] [Related]
44. Halogen Bonding Increases the Potency and Isozyme Selectivity of Protein Arginine Deiminase 1 Inhibitors.
Mondal S; Gong X; Zhang X; Salinger AJ; Zheng L; Sen S; Weerapana E; Zhang X; Thompson PR
Angew Chem Int Ed Engl; 2019 Sep; 58(36):12476-12480. PubMed ID: 31276611
[TBL] [Abstract][Full Text] [Related]
45. Theoretical insights into the protonation states of active site cysteine and citrullination mechanism of Porphyromonas gingivalis peptidylarginine deiminase.
Zhao C; Ling B; Dong L; Liu Y
Proteins; 2017 Aug; 85(8):1518-1528. PubMed ID: 28486790
[TBL] [Abstract][Full Text] [Related]
46. Interrogation of the Active Sites of Protein Arginine Deiminases (PAD1, -2, and -4) Using Designer Probes.
Bello AM; Wasilewski E; Wei L; Moscarello MA; Kotra LP
ACS Med Chem Lett; 2013 Feb; 4(2):249-53. PubMed ID: 24900657
[TBL] [Abstract][Full Text] [Related]
47. Cellular Activity of New Small Molecule Protein Arginine Deiminase 3 (PAD3) Inhibitors.
Jamali H; Khan HA; Tjin CC; Ellman JA
ACS Med Chem Lett; 2016 Sep; 7(9):847-51. PubMed ID: 27660689
[TBL] [Abstract][Full Text] [Related]
48. Treatment of human cardiac fibroblasts with the protein arginine deiminase inhibitor BB-Cl-amidine activates the Nrf2/HO-1 signaling pathway.
Stachowicz A; Sadiq A; Walker B; Sundararaman N; Fert-Bober J
Biomed Pharmacother; 2023 Nov; 167():115443. PubMed ID: 37703660
[TBL] [Abstract][Full Text] [Related]
49. Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis.
Seaman A; Darrah E; Infantino M; Meacci F; Manfredi M; Benucci M; Mahler M
Autoimmun Rev; 2016 Jul; 15(7):776-80. PubMed ID: 26997641
[TBL] [Abstract][Full Text] [Related]
50. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin.
Tarcsa E; Marekov LN; Mei G; Melino G; Lee SC; Steinert PM
J Biol Chem; 1996 Nov; 271(48):30709-16. PubMed ID: 8940048
[TBL] [Abstract][Full Text] [Related]
51. High-Titer Rheumatoid Arthritis Antibodies Preferentially Bind Fibrinogen Citrullinated by Peptidylarginine Deiminase 4.
Blachère NE; Parveen S; Frank MO; Dill BD; Molina H; Orange DE
Arthritis Rheumatol; 2017 May; 69(5):986-995. PubMed ID: 28029744
[TBL] [Abstract][Full Text] [Related]
52. Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization.
Luo Y; Arita K; Bhatia M; Knuckley B; Lee YH; Stallcup MR; Sato M; Thompson PR
Biochemistry; 2006 Oct; 45(39):11727-36. PubMed ID: 17002273
[TBL] [Abstract][Full Text] [Related]
53. Development of a Selective Inhibitor of Protein Arginine Deiminase 2.
Muth A; Subramanian V; Beaumont E; Nagar M; Kerry P; McEwan P; Srinath H; Clancy K; Parelkar S; Thompson PR
J Med Chem; 2017 Apr; 60(7):3198-3211. PubMed ID: 28328217
[TBL] [Abstract][Full Text] [Related]
54. Citrulline Not a Major Determinant in the Recognition of Peptidylarginine Deiminase 2 and 4 by Autoantibodies in Rheumatoid Arthritis.
Darrah E; Davis RL; Curran AM; Naik P; Chen R; Na CH; Giles JT; Andrade F
Arthritis Rheumatol; 2020 Sep; 72(9):1476-1482. PubMed ID: 32255561
[TBL] [Abstract][Full Text] [Related]
55. Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.
Cappelli LC; Konig MF; Gelber AC; Bingham CO; Darrah E
Arthritis Res Ther; 2018 Mar; 20(1):59. PubMed ID: 29566742
[TBL] [Abstract][Full Text] [Related]
56. Citrullination of fibrinogen by peptidylarginine deiminase 2 impairs fibrin clot structure.
Damiana T; Damgaard D; Sidelmann JJ; Nielsen CH; de Maat MPM; Münster AB; Palarasah Y
Clin Chim Acta; 2020 Feb; 501():6-11. PubMed ID: 31730822
[TBL] [Abstract][Full Text] [Related]
57. In vivo expression of peptidylarginine deiminase in Drosophila melanogaster.
Mahneva O; Risley MG; John C; Milton SL; Dawson-Scully K; Ja WW
PLoS One; 2020; 15(1):e0227822. PubMed ID: 31940417
[TBL] [Abstract][Full Text] [Related]
58. S100 and S100 fused-type protein families in epidermal maturation with special focus on S100A3 in mammalian hair cuticles.
Kizawa K; Takahara H; Unno M; Heizmann CW
Biochimie; 2011 Dec; 93(12):2038-47. PubMed ID: 21664410
[TBL] [Abstract][Full Text] [Related]
59. Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.
Shi J; Darrah E; Sims GP; Mustelin T; Sampson K; Konig MF; Bingham CO; Rosen A; Andrade F
Ann Rheum Dis; 2018 Jan; 77(1):141-148. PubMed ID: 29070531
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
